# Phase 2 Study of Erlotinib, Gemcitabine and Oxaliplatin Combination Chemotherapy to Advanced Pancreatic Cancer

> **NCT01505413** · PHASE2 · COMPLETED · sponsor: **Soonchunhyang University Hospital** · enrollment: 33 (actual)

## Conditions studied

- Pancreatic Cancer

## Interventions

- **DRUG:** Erlotinib
- **DRUG:** Gemcitabine
- **DRUG:** Oxaliplatin

## Key facts

- **NCT ID:** NCT01505413
- **Lead sponsor:** Soonchunhyang University Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-01
- **Primary completion:** 2013-12
- **Final completion:** 2014-03
- **Target enrollment:** 33 (ACTUAL)
- **Last updated:** 2014-04-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01505413

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01505413, "Phase 2 Study of Erlotinib, Gemcitabine and Oxaliplatin Combination Chemotherapy to Advanced Pancreatic Cancer". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT01505413. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*